Alpha 2.0
Login Register
» Authors » Angels Vives

Angels Vives

Explore the profile of Angels Vives including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 12
Citations 69
Followers 0
Related Specialties
Gynecology & Obstetrics
General Medicine
Molecular Biology
Top 10 Co-Authors
Elena Carreras
Pablo Garcia-Manau
Eva Lopez-Quesada
Manel Mendoza
Anna Maroto
Erika Bonacina
Lourdes Martin
Monica Lopez
Marta Ricart
Mireia Teixidor
Published In
Acta Obstet Gynecol Scand
Obstet Gynecol Int
BMJ Open
JMIR Res Protoc
Nat Med
Affiliations
Soon will be listed here.
Recent Articles
1.
Angiogenic factors versus fetomaternal Doppler for fetal growth restriction at term: an open-label, randomized controlled trial
Garcia-Manau P, Bonacina E, Martin-Alonso R, Martin L, Palacios A, Sanchez-Camps M, et al.
Nat Med . 2025 Jan; PMID: 39775039
Small fetuses, with estimated fetal weight (EFW) below the tenth percentile, are classified as fetal growth restriction (FGR) or small for gestational age (SGA) based on prenatal ultrasound. FGR fetuses...
2.
Placental growth factor at 24-28 weeks for aspirin discontinuation in pregnancies at high risk for preterm preeclampsia: Post hoc analysis of StopPRE trial
Ricart M, Bonacina E, Garcia-Manau P, Lopez M, Caamina S, Vives A, et al.
Acta Obstet Gynecol Scand . 2024 Aug; 103(11):2273-2280. PMID: 39171611
Introduction: This study aims to evaluate the safety of discontinuing aspirin treatment at 24-28 weeks in women at high risk after first-trimester combined screening for preeclampsia (PE) and normal placental...
3.
Clinical effectiveness of routine first-trimester combined screening for pre-eclampsia in Spain with the addition of placental growth factor
Garcia-Manau P, Bonacina E, Serrano B, Caamina S, Ricart M, Lopez-Quesada E, et al.
Acta Obstet Gynecol Scand . 2023 Oct; 102(12):1711-1718. PMID: 37814344
Introduction: Pre-eclampsia affects 2%-8% of pregnancies and is one of the leading causes of maternal and perinatal morbidity and mortality. First-trimester screening using an algorithm that combines maternal characteristics, mean...
4.
Mid-trimester uterine artery Doppler for aspirin discontinuation in pregnancies at high risk for preterm pre-eclampsia: Post-hoc analysis of StopPRE trial
Bonacina E, Garcia-Manau P, Lopez M, Caamina S, Vives A, Lopez-Quesada E, et al.
BJOG . 2023 Aug; 131(3):334-342. PMID: 37555464
Objective: To assess whether aspirin treatment can be discontinued in pregnancies with normal uterine artery pulsatility index (≤90th percentile) at 24-28 weeks. Design: Post-hoc analysis of a clinical trial. Setting:...
5.
Aspirin Discontinuation at 24 to 28 Weeks' Gestation in Pregnancies at High Risk of Preterm Preeclampsia: A Randomized Clinical Trial
Mendoza M, Bonacina E, Garcia-Manau P, Lopez M, Caamina S, Vives A, et al.
JAMA . 2023 Feb; 329(7):542-550. PMID: 36809321
Importance: Aspirin reduces the incidence of preterm preeclampsia by 62% in pregnant individuals at high risk of preeclampsia. However, aspirin might be associated with an increased risk of peripartum bleeding,...
6.
The Fetal Growth Restriction at Term Managed by Angiogenic Factors Versus Feto-Maternal Doppler (GRAFD) Trial to Avoid Adverse Perinatal Outcomes: Protocol for a Multicenter, Open-Label, Randomized Controlled Trial
Garcia-Manau P, Mendoza M, Bonacina E, Martin-Alonso R, Martin L, Palacios A, et al.
JMIR Res Protoc . 2022 Oct; 11(10):e37452. PMID: 36222789
Background: Fetal smallness affects 10% of pregnancies. Small fetuses are at a higher risk of adverse outcomes. Their management using estimated fetal weight and feto-maternal Doppler has a high sensitivity...
7.
Shared risk factors for COVID-19 and preeclampsia in the first trimester: An observational study
Serrano B, Mendoza M, Garcia-Aguilar P, Bonacina E, Garcia-Ruiz I, Garcia-Manau P, et al.
Acta Obstet Gynecol Scand . 2022 May; 101(7):803-808. PMID: 35505629
Introduction: The association between preeclampsia and coronavirus disease 2019 (COVID-19) is under study. Previous publications have hypothesized the existence of shared risk factors for both conditions or a deficient trophoblastic...
8.
Implementation of routine first-trimester combined screening for preeclampsia based on the Gaussian algorithm: A clinical effectiveness study
Mendoza M, Bonacina E, Serrano B, Ricart M, Martin L, Lopez-Quesada E, et al.
Int J Gynaecol Obstet . 2022 Mar; 159(3):803-809. PMID: 35332556
Objective: To evaluate the clinical effectiveness of the routine first-trimester screening for preeclampsia (PE) after being implemented in six Catalan maternities. Methods: Participants in the reference group were recruited prospectively...
9.
Assessment of an intervention to optimise antenatal management of women admitted with preterm labour and intact membranes using amniocentesis-based predictive risk models: study protocol for a randomised controlled trial (OPTIM-PTL Study)
Cobo T, Aldecoa V, Bartha J, Bugatto F, Paz Carrillo-Badillo M, Comas C, et al.
BMJ Open . 2021 Sep; 11(9):e054711. PMID: 34588268
Introduction: The majority of women admitted with threatened preterm labour (PTL) do not delivery prematurely. While those with microbial invasion of the amniotic cavity (MIAC) represent the highest risk group,...
10.
Prediction of neonatal respiratory morbidity by quantitative ultrasound lung texture analysis: a multicenter study
Palacio M, Bonet-Carne E, Cobo T, Perez-Moreno A, Sabria J, Richter J, et al.
Am J Obstet Gynecol . 2017 Mar; 217(2):196.e1-196.e14. PMID: 28342715
Background: Prediction of neonatal respiratory morbidity may be useful to plan delivery in complicated pregnancies. The limited predictive performance of the current diagnostic tests together with the risks of an...